Advertisement

Risk of Emergent Bradycardia Associated with the Use of Carvedilol and Metoprolol in Routine Clinical Practice

      Abstract

      Background

      Large randomized trials have reported mixed results regarding the risk of bradycardia between metoprolol and carvedilol. We compared the incidence of emergent bradycardia (measured by an emergency department visit or hospitalization due to bradycardia) for patients initiating metoprolol and carvedilol.

      Methods

      Adult beneficiaries of Medi-Cal, the State of California Medicaid program, without a diagnosis of bradycardia who initiated metoprolol or carvedilol between May 1, 2004, and November 1, 2009, were included. Cox proportional hazard regression analysis was performed to model the time to first occurrence of emergent bradycardia after initiation of the study drugs as a dependent variable and the study drug (metoprolol vs carvedilol) as the primary predictor with adjustments for total daily metoprolol-equivalent dose, formulations, and use of nonstudy drugs as time-varying covariates, as well as demographics and comorbidities.

      Results

      Among 38,186 subjects, 77.7% initiated metoprolol and 22.3% initiated carvedilol. The incidence of emergent bradycardia was low and comparable between the drugs (18.1 per 1000 person-years using metoprolol vs 17.7 per 100 person-years using carvedilol; unadjusted hazard ratio, 1.07; 95% confidence interval, 0.76-1.49). However, carvedilol users had substantially different population characteristics compared with metoprolol users. After adjustments for demographics, comorbidities, metoprolol-equivalent dose, formulations, and use of nonstudy drugs, initiation of metoprolol was associated with an increased risk of emergent bradycardia compared with that of carvedilol (adjusted hazard ratio, 1.64; 95% confidence interval, 1.14-2.36).

      Conclusions

      Initiation of metoprolol is associated with an increased risk of emergent bradycardia compared with carvedilol, although the overall incidence of emergent bradycardia is low in routine clinical practice.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gu Q.
        • Burt V.L.
        • Dillon C.F.
        • Yoon S.
        Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the national health and nutrition examination survey, 2001 to 2010.
        Circulation. 2012; 126: 2105-2114
        • Dulin B.
        • Abraham W.T.
        Pharmacology of carvedilol.
        Am J Cardiol. 2004; 93: 3B-6B
        • Morgan T.
        • Snowden R.
        • Butcher L.
        Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance.
        J Cardiovasc Pharmacol. 1987; 10: S124-S129
        • Weber K.
        • Bohmeke T.
        • van der Does R.
        • Taylor S.H.
        Comparison of the hemodynamic effects of metoprolol and carvedilol in hypertensive patients.
        Cardiovasc Drugs Ther. 1996; 10: 113-117
        • Stoschitzky K.
        • Koshucharova G.
        • Zweiker R.
        • et al.
        Differing beta-blocking effects of carvedilol and metoprolol.
        Eur J Heart Fail. 2001; 3: 343-349
        • Billeh R.
        • Hirsh D.
        • Barker C.
        • et al.
        Randomized, double-blind comparison of acute beta1-blockade with 50 mg metoprolol tartrate vs 25 mg carvedilol in normal subjects.
        Congest Heart Fail. 2006; 12: 254-257
        • Bakris G.L.
        • Fonseca V.
        • Katholi R.E.
        • et al.
        Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
        JAMA. 2004; 292: 2227-2236
        • Poole-Wilson P.A.
        • Swedberg K.
        • Cleland J.G.
        • et al.
        Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.
        Lancet. 2003; 362: 7-13
      1. AstraZeneca. Toprol XL package insert. Available at: http://www1.astrazeneca-us.com/pi/toprol-xl.pdf. Accessed November 1, 2012.

        • Packer M.
        • Bristow M.R.
        • Cohn J.N.
        • et al.
        The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
        N Engl J Med. 1996; 334: 1349-1355
      2. Indiana University Division of Clinical Pharmacology. P450 Interaction Table. Available at: http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Accessed November 1, 2012.

        • Parsons L.
        Reducing bias in a propensity score matched-pair sample using greedy matching techniques.
        in: Proceedings of the Twenty-sixth Annual SAS Users Group International Conferences. SAS Institute Inc, Cary, NC2001: 214-226
        • Parker E.D.
        • Margolis K.L.
        • Trower N.K.
        • et al.
        Comparative effectiveness of 2 beta-blockers in hypertensive patients.
        Arch Intern Med. 2012; : 1-7
        • Essebag V.
        • Hadjis T.
        • Platt R.W.
        • Pilote L.
        Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction.
        J Am Coll Cardiol. 2003; 41: 249-254
        • Hauser T.H.
        • Pinto D.S.
        • Josephson M.E.
        • Zimetbaum P.
        Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter.
        Am J Cardiol. 2003; 91: 1437-1441
        • Yusuf S.
        • Camm A.J.
        Sinus tachyarrhythmias and the specific bradycardic agents: a marriage made in heaven?.
        J Cardiovasc Pharmacol Ther. 2003; 8: 89-105
        • Centers for Disease Control (CDC)
        Vital signs: prevalence, treatment, and control of hypertension–United States, 1999-2002 and 2005-2008.
        MMWR Morb Mortal Wkly Rep. 2011; 60: 103-108
      3. Costco Wholesale Corporation. Drug Pricing Information. Available at: http://www2.costco.com/Pharmacy/DrugInformation.aspx?p=1. Accessed November 1, 2012.

        • Kotlyar E.
        • Keogh A.M.
        • Macdonald P.S.
        • Arnold R.H.
        • McCaffrey D.J.
        • Glanville A.R.
        Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma.
        J Heart Lung Transplant. 2002; 21: 1290-1295
        • Self T.
        • Rogers M.L.
        • Mancell J.
        • Soberman J.E.
        Carvedilol therapy after cocaine-induced myocardial infarction in patients with asthma.
        Am J Med Sci. 2011; 342: 56-61
        • Hemeryck A.
        • Lefebvre R.A.
        • De Vriendt C.
        • Belpaire F.M.
        Paroxetine affects metoprolol pharmacokinetics and pharmacodynamics in healthy volunteers.
        Clin Pharmacol Ther. 2000; 67: 283-291